Gossamer Bio (GOSS)
(Delayed Data from NSDQ)
$0.91 USD
+0.02 (1.98%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $0.91 0.00 (0.14%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
GOSS 0.91 +0.02(1.98%)
Will GOSS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GOSS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GOSS
Gossamer Bio (GOSS) Q2 Earnings and Revenues Lag Estimates
Should You Buy Gossamer Bio (GOSS) After Golden Cross?
GOSS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Gossamer Bio (GOSS) Upgraded to Buy: What Does It Mean for the Stock?
Gossamer Bio (GOSS) Loses -13.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
What Makes Gossamer Bio (GOSS) a New Buy Stock
Other News for GOSS
Buy Rating Affirmed for Gossamer Bio Amidst Financial Growth and Clinical Advancements
Barclays Reaffirms Their Hold Rating on Gossamer Bio (GOSS)
Analysts Offer Insights on Healthcare Companies: Meiragtx Holdings (MGTX), Spruce Biosciences (SPRB) and Gossamer Bio (GOSS)
Piper Sandler Keeps Their Buy Rating on Gossamer Bio (GOSS)
Gossamer Bio: Q2 Earnings Snapshot